Asthma

Atrial Fibrillation

Autoimmune Diseases

Biosimilars

Blood Cancer

COVID-19

Cardiovascular Diseases

Dermatology

Diabetes

Digital Health

Eyecare

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pediatrics

Plaque Psoriasis

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Reproductive Health

Respiratory Conditions

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Supplements And Featured Publications

Events

2023 PBMI Annual National Conference

Virtual Events

CME/CE

Resources

PBM Leaders

Subscribe

Print Subscription

eNewsletter

Articles

The FDA has approved GSK’s myelofibrosis drug, as well as a new indication for Jardiance and a new dosing regimen for Talicia. The agency has also issued a complete response letter for epinephrine nasal spray and assigned a review date for the gene therapy atidarsagene autotemcel.

FDA Updates for the Week of Sept. 18, 2023

Swoop, a New York-based company, has launched an algorithm that may help people with multiple sclerosis take medications as prescribed.

AI Algorithm May Predict Medication Adherence in Patients with MS

Lindsay Zimmerman, Ph.D., M.P.H., vice president of Bartosch Patient Activation Institute at Upfront Healthcare, is one of the 12 up-and-coming leaders in healthcare included in the annual Managed Healthcare Executive feature.

Emerging Leaders in Healthcare: Lindsay Zimmerman of Upfront Healthcare

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistences on the prices of both generics and branded products.

Study Highlights PBMs’ Role in Drug Prices

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Informations

Managed Healthcare Executive

Facebook

Twitter

LinkedIn

Resource Centers

Covid-19

Eye Care

Spotlight

AMCP Annual

ASRS

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

But payers may be putting undue emphasis on interchangeability, said a panelist at session on biosimilars at the 2023 Asembia Specialty Pharmacy Summit. 

Biosimilars, Once Dubious, Looking Like a Surer Thing | 2023 Asembia Specialty Pharmacy Summit

Skylar Jeremias

Articles